Bellerophon drops as late-stage COVID-19 treatment trial put on hold

Bellerophon Therapeutics

23/11/2020 18:48

** Drug developer's  BLPH.O  shares drop 18.7% to $7.14,
among top three percentage decliners in the NASDAQ
    ** Co has put a late-stage study of its COVID-19 treatment,
INOpulse, on hold after completing an interim analysis, which
evaluated safety and a single efficacy endpoint of respiratory
failure or death (RFD)  urn:newsml:reuters.com:*:nGNX6QfdhB
    ** Says the interim analysis, carried out on 100 out of 200
patients recruited, included 10 RFD events, representing a small
sample size for evaluation of the RFD endpoint
    ** "We intend to complete the study procedures for the
remaining patients and evaluate the full data set ... in order
to assess potential next steps in our COVID-19 program," says
CEO Fabian Tenenbaum
    ** Co received emergency use authorization from FDA for its
inhaled nitric oxide therapy, INOpulse, as a treatment for
COVID-19 in March  urn:newsml:reuters.com:*:nGNX4xv4Zc 
    ** Including session losses, stock has risen ~38% YTD

 (Reporting by Bhanvi Satija)
 ((Bhanvi.Satija@thomsonreuters.com;))